Fig. 1: Next decade research agenda for neo(adjuvant) immunotherapy in TNBC.
From: Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Abbreviations: IO, immunotherapy, TNBC, triple negative breast cancer; TMB, tumor mutational burden; ADC, antibody-drug conjugate; ER, estrogen receptor; CD, cluster of differentiation; TILs, tumor infiltrating lymphocytes; PD-L1, Programmed death-ligand 1; HLA, human leukocyte antigen; PD-1, Programmed cell death protein 1; A, adenosine; T, thymine; C, cytosine; G, guanine; BRCA, BReast CAncer gene; EFS, event-freee survival; RD, residual disease; me1, mono-methylated form; BC, breast cancer. Created with biorender.com.
